Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte precursor cell | 12 studies | 46% ± 22% | |
astrocyte | 12 studies | 36% ± 19% | |
GABAergic neuron | 9 studies | 39% ± 22% | |
interneuron | 6 studies | 38% ± 20% | |
glutamatergic neuron | 5 studies | 27% ± 10% | |
GABAergic interneuron | 3 studies | 33% ± 4% | |
neuron | 3 studies | 24% ± 3% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 5 studies | 32% ± 15% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 95% | 218.74 | 2508 / 2642 | 78% | 4.08 | 552 / 705 |
adrenal gland | 41% | 34.29 | 107 / 258 | 50% | 3.59 | 116 / 230 |
intestine | 81% | 177.16 | 782 / 966 | 1% | 0.10 | 6 / 527 |
skin | 11% | 4.29 | 196 / 1809 | 65% | 6.28 | 308 / 472 |
eye | 0% | 0 | 0 / 0 | 74% | 4.95 | 59 / 80 |
esophagus | 65% | 88.05 | 934 / 1445 | 3% | 0.04 | 5 / 183 |
ovary | 18% | 7.87 | 33 / 180 | 49% | 2.16 | 210 / 430 |
thymus | 14% | 5.61 | 91 / 653 | 45% | 3.50 | 275 / 605 |
bladder | 48% | 23.19 | 10 / 21 | 3% | 0.11 | 16 / 504 |
breast | 45% | 32.92 | 207 / 459 | 4% | 0.12 | 44 / 1118 |
stomach | 35% | 36.12 | 125 / 359 | 1% | 0.05 | 4 / 286 |
adipose | 34% | 23.11 | 409 / 1204 | 0% | 0 | 0 / 0 |
lung | 17% | 8.67 | 96 / 578 | 9% | 0.33 | 104 / 1155 |
uterus | 15% | 9.10 | 26 / 170 | 9% | 1.94 | 40 / 459 |
prostate | 21% | 10.50 | 52 / 245 | 0% | 0.00 | 1 / 502 |
muscle | 18% | 8.50 | 142 / 803 | 0% | 0 | 0 / 0 |
kidney | 3% | 4.84 | 3 / 89 | 4% | 0.12 | 36 / 901 |
blood vessel | 5% | 2.79 | 72 / 1335 | 0% | 0 | 0 / 0 |
heart | 5% | 1.78 | 40 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.30 | 1 / 29 |
tonsil | 0% | 0 | 0 / 0 | 2% | 0.05 | 1 / 45 |
pancreas | 0% | 0.09 | 1 / 328 | 2% | 0.48 | 3 / 178 |
spleen | 1% | 0.38 | 2 / 241 | 0% | 0 | 0 / 0 |
liver | 0% | 0.23 | 1 / 226 | 0% | 0 | 0 / 406 |
peripheral blood | 0% | 0.04 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0097009 | Biological process | energy homeostasis |
GO_0045664 | Biological process | regulation of neuron differentiation |
GO_0060159 | Biological process | regulation of dopamine receptor signaling pathway |
GO_0021766 | Biological process | hippocampus development |
GO_0007169 | Biological process | cell surface receptor protein tyrosine kinase signaling pathway |
GO_0090648 | Biological process | response to environmental enrichment |
GO_0007165 | Biological process | signal transduction |
GO_0007275 | Biological process | multicellular organism development |
GO_0038083 | Biological process | peptidyl-tyrosine autophosphorylation |
GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
GO_0033674 | Biological process | positive regulation of kinase activity |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_1900006 | Biological process | positive regulation of dendrite development |
GO_0036269 | Biological process | swimming behavior |
GO_0048666 | Biological process | neuron development |
GO_0050995 | Biological process | negative regulation of lipid catabolic process |
GO_0030534 | Biological process | adult behavior |
GO_0016310 | Biological process | phosphorylation |
GO_0046777 | Biological process | protein autophosphorylation |
GO_0042127 | Biological process | regulation of cell population proliferation |
GO_0043235 | Cellular component | receptor complex |
GO_0005886 | Cellular component | plasma membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0032991 | Cellular component | protein-containing complex |
GO_0008201 | Molecular function | heparin binding |
GO_0004713 | Molecular function | protein tyrosine kinase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0004714 | Molecular function | transmembrane receptor protein tyrosine kinase activity |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
GO_0030298 | Molecular function | receptor signaling protein tyrosine kinase activator activity |
Gene name | ALK |
Protein name | Anaplastic lymphoma kinase SEC31A/ALK fusion protein Uncharacterized protein ALK Tyrosine-protein kinase receptor (EC 2.7.10.1) ALK receptor tyrosine kinase ALK tyrosine kinase receptor (EC 2.7.10.1) (Anaplastic lymphoma kinase) (CD antigen CD246) |
Synonyms | STRN fusion SEC31A |
Description | FUNCTION: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system . Also acts as a key thinness protein involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a negative regulator of white adipose tissue lipolysis and sympathetic tone to fine-tune energy homeostasis (By similarity). Following activation by ALKAL2 ligand at the cell surface, transduces an extracellular signal into an intracellular response . In contrast, ALKAL1 is not a potent physiological ligand for ALK . Ligand-binding to the extracellular domain induces tyrosine kinase activation, leading to activation of the mitogen-activated protein kinase (MAPK) pathway . Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif . Induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1 . ALK activation may also be regulated by pleiotrophin (PTN) and midkine (MDK) . PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation . MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction . Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase . Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK . . |
Accessions | B2MXD8 B2MXE2 B6D4Y8 F0UY65 D1MAM2 B2MXE3 ENST00000618119.4 Q580I3 B2MXE1 B6D4Y3 ENST00000453137.1 A0A087WZL3 B2MXE7 B2MXD7 D1MAM0 B6D4Y5 B2MXE0 B6D4Y1 D1MAM1 B6D4Y7 ENST00000431873.6 Q9UM73 D1MAM5 D1MAM3 B2MXD9 B2MXE5 B2MXE6 F0UY66 ENST00000389048.8 A0A097F6U9 B6D4Y6 D1MAM4 B6D4Y2 ENST00000642122.1 B2MXE4 H7BZ33 A0A0K2YUJ3 E7EPW7 A0A024A2P5 |